At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous ...

Request for FDA Rolling Review submitted to FDA on January 30, 2026 Non-Clinical and CMC BLA modules submitted to FDA At FDA's request, Type D Meeting expected in March 2026 to review Comparative ...

The School of Psychology at the University of Southampton is seeking to make a strategic appointment of a part time permanent 0.4 FTE post to support education and training, and more specifically ...

Researchers need to understand their responsibilities when using the UBIRB as IRB for multi-site research. This UB CTSI Watch and Learn educational module video outlines: Researcher responsibilities ...

Questions? Learn more about RF Study Card Programs by contacting [email protected] and about card programs by contacting [email protected]. Contact Valerie Dennis, Director of ...

1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical ...

Our CVIS (Cardiovascular Information Management System) is a unique software solution that empowers you to improve the clinical and financial performance of your cardiology department. Clinical ...

New Market Briefing From Black Book Research Highlights 80% of Surveyed Hospitals Active in EHR Initiatives and Accelerating Demand for SATUSEHAT Interoperability Operations LONDON, GB / ACCESS ...

New York, New York--(Newsfile Corp. - February 2, 2026) - OS Therapies Inc. (OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced that it ...